Alembic Pharmaceuticals Limited has informed the Exchange regarding a press release dated March 06, 2026, titled "Alembic Pharmaceuticals Reports First Prescription Sale of Pivya® (pivmecillinam) Following US Commercial Launch through Alembic Therapeutics LLC".
APLLTD · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Alembic Pharmaceuticals has reported the first prescription-based sale of Pivya® (pivmecillinam) tablets in the United States, marking the company's entry into the US branded pharmaceuticals market. Pivya® is an oral prescription antibiotic used as a first-line treatment for uncomplicated urinary tract infections (uUTIs) in women, targeting a market of roughly 30 million prescriptions annually. The product is being sold through Alembic Therapeutics LLC, a step-down wholly owned US subsidiary. This is Alembic's first branded product in the US, complementing its established generics business. The company plans a phased expansion of its field force as prescription momentum builds, with the launch stemming from a prior strategic acquisition.
This is a strategic milestone that opens a new growth avenue in the higher-margin US branded specialty segment. Positive for long-term value creation, though meaningful revenue contribution from Pivya® will likely take time to scale as the field force and physician adoption expand.